Bases de données pharmaceutiques : Questions médicales fréquentes
Nom anglais: Databases, Pharmaceutical
Descriptor UI:D062313
Tree Number:L01.470.750.750.400
Termes MeSH sélectionnés :
Double-Blind Method
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Bases de données pharmaceutiques : Questions médicales les plus fréquentes",
"headline": "Bases de données pharmaceutiques : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Bases de données pharmaceutiques : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-02-05",
"dateModified": "2025-04-30",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Bases de données pharmaceutiques"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Bases de données factuelles",
"url": "https://questionsmedicales.fr/mesh/D016208",
"about": {
"@type": "MedicalCondition",
"name": "Bases de données factuelles",
"code": {
"@type": "MedicalCode",
"code": "D016208",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "L01.470.750.750"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Bases de données pharmaceutiques",
"alternateName": "Databases, Pharmaceutical",
"code": {
"@type": "MedicalCode",
"code": "D062313",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Michele B Kaufman",
"url": "https://questionsmedicales.fr/author/Michele%20B%20Kaufman",
"affiliation": {
"@type": "Organization",
"name": ""
}
},
{
"@type": "Person",
"name": "Konstantinos Vezertzis",
"url": "https://questionsmedicales.fr/author/Konstantinos%20Vezertzis",
"affiliation": {
"@type": "Organization",
"name": "School of Electrical and Computer Engineering, Biomedical Engineering Laboratory, National Technical University of Athens, Heroon Polytecniou 9, Athens, 15780, Athens, Greece."
}
},
{
"@type": "Person",
"name": "George I Lambrou",
"url": "https://questionsmedicales.fr/author/George%20I%20Lambrou",
"affiliation": {
"@type": "Organization",
"name": "School of Electrical and Computer Engineering, Biomedical Engineering Laboratory, National Technical University of Athens, Heroon Polytecniou 9, Athens, 15780, Athens, Greece."
}
},
{
"@type": "Person",
"name": "Dimitrios Koutsouris",
"url": "https://questionsmedicales.fr/author/Dimitrios%20Koutsouris",
"affiliation": {
"@type": "Organization",
"name": "School of Electrical and Computer Engineering, Biomedical Engineering Laboratory, National Technical University of Athens, Heroon Polytecniou 9, Athens, 15780, Athens, Greece."
}
},
{
"@type": "Person",
"name": "Piotr Ozieranski",
"url": "https://questionsmedicales.fr/author/Piotr%20Ozieranski",
"affiliation": {
"@type": "Organization",
"name": "Department of Social and Policy Sciences, University of Bath, Bath, United Kingdom."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Preemptive analgesia for hemorrhoidectomy: study protocol for a prospective, randomized, double-blind trial.",
"datePublished": "2022-06-27",
"url": "https://questionsmedicales.fr/article/35761383",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s13063-022-06107-0"
}
},
{
"@type": "ScholarlyArticle",
"name": "Melatonin for migraine prevention in children and adolescents: A randomized, double-blind, placebo-controlled trial after single-blind placebo lead-in.",
"datePublished": "2023-07-19",
"url": "https://questionsmedicales.fr/article/37466211",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/head.14600"
}
},
{
"@type": "ScholarlyArticle",
"name": "Clonidine augmentation in patients with schizophrenia: A double-blind, randomized placebo-controlled trial.",
"datePublished": "2023-03-28",
"url": "https://questionsmedicales.fr/article/36989672",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.schres.2023.03.039"
}
},
{
"@type": "ScholarlyArticle",
"name": "Double-Blind Placebo-Controlled Study of Memantine in Trichotillomania and Skin-Picking Disorder.",
"datePublished": "2023-02-22",
"url": "https://questionsmedicales.fr/article/36856701",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1176/appi.ajp.20220737"
}
},
{
"@type": "ScholarlyArticle",
"name": "Double blind trial of a deuterated form of linoleic acid (RT001) in Friedreich ataxia.",
"datePublished": "2022-12-03",
"url": "https://questionsmedicales.fr/article/36462055",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s00415-022-11501-4"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Sciences de l'information",
"item": "https://questionsmedicales.fr/mesh/D007254"
},
{
"@type": "ListItem",
"position": 3,
"name": "Mémorisation et recherche des informations",
"item": "https://questionsmedicales.fr/mesh/D016247"
},
{
"@type": "ListItem",
"position": 4,
"name": "Bases de données comme sujet",
"item": "https://questionsmedicales.fr/mesh/D019992"
},
{
"@type": "ListItem",
"position": 5,
"name": "Bases de données factuelles",
"item": "https://questionsmedicales.fr/mesh/D016208"
},
{
"@type": "ListItem",
"position": 6,
"name": "Bases de données pharmaceutiques",
"item": "https://questionsmedicales.fr/mesh/D062313"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Bases de données pharmaceutiques - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Bases de données pharmaceutiques",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-15",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Bases de données pharmaceutiques",
"description": "Comment identifier un médicament dans une base de données ?\nQuelles informations sont disponibles sur les effets secondaires ?\nComment vérifier les interactions médicamenteuses ?\nPeut-on trouver des informations sur les médicaments génériques ?\nComment évaluer l'efficacité d'un médicament ?",
"url": "https://questionsmedicales.fr/mesh/D062313?mesh_terms=Double-Blind+Method&page=2#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Bases de données pharmaceutiques",
"description": "Où trouver des informations sur les symptômes liés à un médicament ?\nComment les symptômes sont-ils classés dans les bases ?\nLes bases fournissent-elles des exemples de symptômes ?\nComment les symptômes sont-ils liés aux médicaments ?\nPeut-on trouver des symptômes rares dans les bases ?",
"url": "https://questionsmedicales.fr/mesh/D062313?mesh_terms=Double-Blind+Method&page=2#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Bases de données pharmaceutiques",
"description": "Les bases fournissent-elles des conseils de prévention ?\nComment prévenir les interactions médicamenteuses ?\nY a-t-il des recommandations pour les populations à risque ?\nComment les bases aident-elles à la prévention des maladies ?\nPeut-on trouver des stratégies de prévention dans les bases ?",
"url": "https://questionsmedicales.fr/mesh/D062313?mesh_terms=Double-Blind+Method&page=2#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Bases de données pharmaceutiques",
"description": "Comment rechercher des traitements dans une base de données ?\nLes bases incluent-elles des protocoles de traitement ?\nComment comparer l'efficacité de différents traitements ?\nPeut-on trouver des alternatives aux traitements ?\nComment les traitements sont-ils mis à jour dans les bases ?",
"url": "https://questionsmedicales.fr/mesh/D062313?mesh_terms=Double-Blind+Method&page=2#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Bases de données pharmaceutiques",
"description": "Comment identifier les complications liées à un médicament ?\nLes bases fournissent-elles des études de cas sur les complications ?\nComment les complications sont-elles signalées dans les bases ?\nPeut-on trouver des statistiques sur les complications ?\nComment prévenir les complications médicamenteuses ?",
"url": "https://questionsmedicales.fr/mesh/D062313?mesh_terms=Double-Blind+Method&page=2#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Bases de données pharmaceutiques",
"description": "Quels facteurs de risque sont associés aux médicaments ?\nComment les bases évaluent-elles les facteurs de risque ?\nPeut-on trouver des recommandations sur les facteurs de risque ?\nComment les facteurs de risque influencent-ils le traitement ?\nLes bases incluent-elles des informations sur les facteurs de risque environnementaux ?",
"url": "https://questionsmedicales.fr/mesh/D062313?mesh_terms=Double-Blind+Method&page=2#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment identifier un médicament dans une base de données ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Utilisez le nom commercial, le principe actif ou le code ATC pour rechercher."
}
},
{
"@type": "Question",
"name": "Quelles informations sont disponibles sur les effets secondaires ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les bases fournissent des listes d'effets indésirables et leur fréquence."
}
},
{
"@type": "Question",
"name": "Comment vérifier les interactions médicamenteuses ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Consultez les sections dédiées aux interactions dans les bases de données."
}
},
{
"@type": "Question",
"name": "Peut-on trouver des informations sur les médicaments génériques ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les bases de données incluent des informations sur les équivalents génériques."
}
},
{
"@type": "Question",
"name": "Comment évaluer l'efficacité d'un médicament ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Recherchez des études cliniques et des revues systématiques dans les bases."
}
},
{
"@type": "Question",
"name": "Où trouver des informations sur les symptômes liés à un médicament ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les bases de données listent les symptômes associés aux effets secondaires."
}
},
{
"@type": "Question",
"name": "Comment les symptômes sont-ils classés dans les bases ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils sont souvent classés par système corporel ou par fréquence d'apparition."
}
},
{
"@type": "Question",
"name": "Les bases fournissent-elles des exemples de symptômes ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles incluent des exemples pour chaque médicament et ses effets."
}
},
{
"@type": "Question",
"name": "Comment les symptômes sont-ils liés aux médicaments ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les bases établissent des liens entre médicaments et symptômes rapportés."
}
},
{
"@type": "Question",
"name": "Peut-on trouver des symptômes rares dans les bases ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les bases documentent également des effets indésirables rares."
}
},
{
"@type": "Question",
"name": "Les bases fournissent-elles des conseils de prévention ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles incluent des recommandations pour éviter les effets indésirables."
}
},
{
"@type": "Question",
"name": "Comment prévenir les interactions médicamenteuses ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Consultez les bases pour identifier les médicaments à éviter ensemble."
}
},
{
"@type": "Question",
"name": "Y a-t-il des recommandations pour les populations à risque ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les bases fournissent des conseils spécifiques pour les groupes vulnérables."
}
},
{
"@type": "Question",
"name": "Comment les bases aident-elles à la prévention des maladies ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles offrent des informations sur les médicaments préventifs et leur utilisation."
}
},
{
"@type": "Question",
"name": "Peut-on trouver des stratégies de prévention dans les bases ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles incluent des stratégies basées sur des données probantes pour la prévention."
}
},
{
"@type": "Question",
"name": "Comment rechercher des traitements dans une base de données ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Utilisez des mots-clés comme le nom du médicament ou la pathologie traitée."
}
},
{
"@type": "Question",
"name": "Les bases incluent-elles des protocoles de traitement ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles fournissent des recommandations et des protocoles basés sur des preuves."
}
},
{
"@type": "Question",
"name": "Comment comparer l'efficacité de différents traitements ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Consultez les études comparatives et les méta-analyses disponibles."
}
},
{
"@type": "Question",
"name": "Peut-on trouver des alternatives aux traitements ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les bases proposent souvent des alternatives thérapeutiques."
}
},
{
"@type": "Question",
"name": "Comment les traitements sont-ils mis à jour dans les bases ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les bases sont régulièrement mises à jour avec les dernières recherches et recommandations."
}
},
{
"@type": "Question",
"name": "Comment identifier les complications liées à un médicament ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les bases de données listent les complications possibles et leur fréquence."
}
},
{
"@type": "Question",
"name": "Les bases fournissent-elles des études de cas sur les complications ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles incluent des études de cas documentant des complications spécifiques."
}
},
{
"@type": "Question",
"name": "Comment les complications sont-elles signalées dans les bases ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles sont souvent signalées par des professionnels de santé et des patients."
}
},
{
"@type": "Question",
"name": "Peut-on trouver des statistiques sur les complications ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les bases fournissent des données statistiques sur la fréquence des complications."
}
},
{
"@type": "Question",
"name": "Comment prévenir les complications médicamenteuses ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les bases offrent des recommandations pour minimiser les risques de complications."
}
},
{
"@type": "Question",
"name": "Quels facteurs de risque sont associés aux médicaments ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les bases identifient des facteurs comme l'âge, le sexe et les comorbidités."
}
},
{
"@type": "Question",
"name": "Comment les bases évaluent-elles les facteurs de risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles utilisent des études épidémiologiques et des données cliniques pour évaluer."
}
},
{
"@type": "Question",
"name": "Peut-on trouver des recommandations sur les facteurs de risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les bases fournissent des recommandations pour gérer les facteurs de risque."
}
},
{
"@type": "Question",
"name": "Comment les facteurs de risque influencent-ils le traitement ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils peuvent modifier le choix du médicament et la posologie recommandée."
}
},
{
"@type": "Question",
"name": "Les bases incluent-elles des informations sur les facteurs de risque environnementaux ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent inclure des facteurs environnementaux influençant l'efficacité."
}
}
]
}
]
}
Hemorrhoidectomy is associated with intense postoperative pain that requires multimodal analgesia. It includes nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen, and local anesthetics to re...
Patients of our clinic who meet the following inclusion criteria are included: hemorrhoids grade III-IV and the planned Milligan-Morgan hemorrhoidectomy. After signing the consent all participants are...
Multimodality pain management has been shown to improve pain control and decrease opioid intake in patients after hemorrhoidectomy in several studies. Gabapentin can be considered as an alternative ap...
ClinicalTrial.gov NCT04361695 . Registered on April 24, 2020, version 1.0....
Melatonin is effective for migraine prevention in adults. We hypothesized that melatonin would also be effective for migraine prevention in children and adolescents....
This was a randomized, double-blind trial of melatonin (3 mg or 6 mg) versus placebo for migraine prevention in 10-17 year-olds with 4-28/28 headache days at baseline. Participants were recruited from...
The study closed early due to slow enrollment (n = 72). Two participants were in the single-blind phase when the study closed, therefore the meaningful n = 70. Sixteen percent (11/70) were lost to fol...
When compared to recall at enrollment, headache days decreased across the single-blind placebo phase and the double-blind phase. There was no suggestion of superiority of melatonin; however, given the...
Noradrenergic imbalance in the brain of schizophrenia patients may underlie both symptomatology and deficits in basic information processing. The current study investigated whether augmentation with t...
In a double-blind placebo-controlled randomized clinical trial, 32 chronic schizophrenia patients were randomly assigned to six-weeks augmentation with either 50 μg clonidine or placebo to their curre...
Only patients treated with clonidine showed significantly reduced PANSS negative, general and total scores at follow-up compared to baseline. On average, also patients treated with placebo showed mino...
Only patients treated with clonidine showed a significant decrease on two out of the three PANSS subscales, while additionally retained their levels of sensorimotor gating. Given that there are only a...
Trichotillomania and skin-picking disorder are underrecognized and often disabling conditions in which individuals repeatedly pull at their hair or pick at their skin, leading to noticeable hair loss ...
One hundred adults with trichotillomania or skin-picking disorder (86 women; mean age, 31.4 years [SD=10.2]) were enrolled in a double-blind trial of memantine (dosing range, 10-20 mg/day) or placebo ...
Compared with placebo, memantine treatment was associated with significant improvements in scores on the NIMH scale, Sheehan Disability Scale, and Clinical Global Impressions severity scale in terms o...
This study found that memantine treatment resulted in statistically significant reductions in hair pulling and skin-picking symptoms compared with placebo, with relatively high efficacy (based on numb...
Friedreich ataxia is (FRDA) an autosomal recessive neurodegenerative disorder associated with intrinsic oxidative damage, suggesting that decreasing lipid peroxidation (LPO) might ameliorate disease p...
Sixty-five subjects were recruited across six sites and received either placebo or active drug for an 11-month study. Subjects were evaluated at 0, 4, 9, and 11 months, with the primary outcome measur...
Forty-five subjects completed the protocol. RT001 was well tolerated, with no serious adverse events related to drug. Plasma and red blood cell (RBC) membrane levels of D2-LA and its primary metabolit...
The results of this study provide no evidence for a significant benefit of RT001 at the dosages tested in this Friedreich ataxia patient population....
Periodontitis is a persistent inflammatory condition. Eliminating the infection and reducing its risk factors are the first steps in treating periodontitis. When the anti-infective therapy is complete...
This double-blind randomized placebo-controlled trial included 28 candidates for pocket elimination surgery referred to the private office of a periodontist in Bandar Abbas, Iran, from April 18 to Aug...
Four weeks after intervention, BOP was significantly lower with Anaheal compared to placebo (0% vs. 35.7%, P = 0.014). However, there was no significant difference in GI between groups (P = 0.120). Me...
One-week treatment with Anaheal at a dose of 1 g/d after pocket elimination surgery resulted in significantly lower BOP compared to placebo....
Iranian Registry of Clinical Trials (IRCT), IRCT20201106049289N1. Registered 06/04/2021. Registered prospectively, https://www.irct.ir/trial/52181 ....
Excess fluid accumulation (seroma/hematoma) around the breast implant after reconstruction can lead to significant complications. Topical administration of tranexamic acid (TXA) may reduce fluid accum...
This paired, double-blind, randomized, controlled trial enrolled patients undergoing bilateral mastectomies with immediate direct-to-implant reconstruction. In each patient, one breast was randomized ...
Fifty-three eligible patients, representing 106 breasts, were enrolled. All patients underwent bilateral nipple-sparing mastectomies. After randomization, TXA was placed in the right breast in 30 pati...
Soaking the mastectomy bed with 3% topical TXA before implant insertion leads to a decrease in drain output and a decrease in complications. Topical administration of TXA represents an option to decre...
Therapeutic, I....
Infantile colic is a common problem during the first three months of life. This randomized, double-blind, placebo-controlled trial conducted in an urban hospital in Delhi, India evaluated the efficacy...
One hundred sixty-two clinically healthy infants aged < 5 months age [mean (SD) = 63.5 (30.5) days] fulfilling the Rome-IV diagnostic criteria for infantile colic were enrolled. Eligible children were...
At the end of four weeks, mean (SD) crying or fussing time (min/d) was significantly shorter in infants receiving lactase in comparison to placebo [89.9 (115.2) vs.178.5 (153.2); P = 0.001]. The mean ...
Oral lactase treatment in infantile colic results in symptomatic relief in terms of shortening of duration of crying or fussing, and better parental satisfaction....
Clinical trial registry of India (CTRI/2017/12/010930) registered on 20/12/2017....
Intraoperative hemostasis should be performed with great caution because bleeding is a huge enemy of patient safety during surgery. Tranexamic acid is a lysine synthetic derivate that inhibits fibrino...
The authors conducted a multicenter, double-blind, randomized, controlled clinical trial in patients who were scheduled for liposculpture in three plastic surgery centers (Colombia and Mexico) between...
The authors found the intravenous intervention group to have a greater hemoglobin level than the other two groups on both the first postoperative day ( p = 0.0001) and the fifth postoperative day ( p ...
Intravenous tranexamic acid is a good therapeutic choice to implement on liposculpture procedures to decrease postoperative bleeding....
The preoperative use of intravenous tranexamic acid not only decreases the bleeding rate after liposuction procedures, but also allows greater lipoaspirate volumes when performing high-definition lipo...
Therapeutic, I....
Subcision method is one of the main techniques for treatment of acne scars or stromal-vascular fraction (SVF) and combined therapy can improve treatment strategy....
To use subcision method along with SVF for treatment of acne scar and comprised with alone subcision method....
In this double-blind clinical trial study, 10 patients with acne scars were entered into the study. Subcision technique was randomly performed on one side of the face and subcision technique plus SVF ...
In terms of volume and area of scars, the mean percent change was 46.55 ± 13.92 and 44.60 ± 5.76, for the case group, and 13.31 ± 9.27 and 11.28 ± 9.64 for the control group, respectively. So, combine...
According to the acquired results, combined therapy can be considered as effective and safe treatment for acne scars with significant higher efficacy compared with subcision alone....